HILLSIDE, NJ / ACCESSWIRE / November 13, 2019 / Integrated BioPharma, Inc. (OTC BB:INBP) (the “Company”) reports it financial results for the quarter ended September 30, 2019.
Revenue for the quarter ended September 30, 2019 was $11.4 million compared to $10.3 million for the quarter ended September 30, 2018, an increase of $1.1 million or 10.7%. The Company had operating income for the quarter ended September 30, 2019 of $0.5 million compared to operating income of $0.4 million for the quarter ended September 30, 2018.
For the quarter ended September 30, 2019, the Company had net income and diluted net income of $0.3 million or $0.01 per share of common stock, compared with net income and diluted net income of $0.2 million or $0.01 per share of common stock for the quarter ended September 30, 2018.
“We are excited to report that our revenue increased by approximately 11% in the quarter ended September 30, 2019 and that our revenue from our two significant customers in our Contract Manufacturing Segment remained consistent; representing approximately 91% and 89% of total revenue in the quarters ended September 30, 2019 and 2018, respectively,” said Riva Sheppard, Co-Chief Executive Officer of the Company.
A summary of our financial results for the three months ended September 30, 2019 follows:
|
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
|
||||||||
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
|
||||||||
|
(In thousands, except share and per share amounts)
|
||||||||
|
(unaudited)
|
||||||||
|
|
Three Months Ended | |||||||
|
|
September 30, | |||||||
|
|
2019 | 2018 | ||||||
|
|
||||||||
|
Total revenue
|
$ | 11,406 | $ | 10,304 | ||||
|
Cost of sales
|
10,007 | 9,085 | ||||||
|
Gross profit
|
1,399 | 1,219 | ||||||
|
Selling and administrative expenses
|
923 | 814 | ||||||
|
Operating income
|
476 | 405 | ||||||
|
Other expense, net (1)
|
(127 | ) | (191 | ) | ||||
|
|
||||||||
|
Income before income taxes
|
349 | 214 | ||||||
|
Income tax expense, net
|
37 | 55 | ||||||
|
Net income
|
$ | 312 | $ | 159 | ||||
|
|
||||||||
|
Net income per common share:
|
||||||||
|
Basic
|
$ | 0.01 | $ | 0.01 | ||||
|
Diluted
|
$ | 0.01 | $ | 0.01 | ||||
|
Weighted average common shares outstanding:
|
||||||||
|
Basic
|
29,565,943 | 27,218,786 | ||||||
|
Diluted
|
30,724,633 | 27,963,604 | ||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
(1) Includes interest expense of $124 and $200, respectively.
|
||||||||
SOURCE: Integrated BioPharma, Inc.
View source version on accesswire.com:
https://www.accesswire.com/566451/Integrated-BioPharma-Reports-Results-for-its-Quarter-Ended-September-30-2019
NEWTOWN, Pa., Dec. 22, 2024 /PRNewswire/ -- The law firm of Edelson Lechtzin LLP is…
Miami, Florida--(Newsfile Corp. - December 21, 2024) - Amid the vibrant backdrop of Art Basel…
Daily Fit Notes, founded by Justin Brey in New York, launches a text-based subscription fitness…
MT. STERLING, Ohio, Dec. 20, 2024 /PRNewswire/ -- WillowWood, a global leader in prosthetic solutions,…
TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"…
Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…